VIRGINIA RETIREMENT SYSTEMS ET Al Sells 5,800 Shares of Krystal Biotech, Inc. $KRYS

VIRGINIA RETIREMENT SYSTEMS ET Al reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 74.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,000 shares of the company’s stock after selling 5,800 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Krystal Biotech were worth $353,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of KRYS. State Street Corp lifted its stake in Krystal Biotech by 10.5% in the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after purchasing an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. lifted its stake in shares of Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares during the last quarter. Braidwell LP lifted its position in Krystal Biotech by 81.6% in the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after buying an additional 327,067 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Krystal Biotech by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock worth $85,174,000 after purchasing an additional 7,194 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Krystal Biotech by 173.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock worth $103,764,000 after purchasing an additional 365,304 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 0.9%

Shares of Krystal Biotech stock opened at $244.71 on Tuesday. The stock’s fifty day moving average price is $222.66 and its 200-day moving average price is $179.75. The firm has a market cap of $7.10 billion, a P/E ratio of 36.69 and a beta of 0.46. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $265.92.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The company had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. Analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Analysts Set New Price Targets

KRYS has been the subject of a number of recent analyst reports. Chardan Capital boosted their price objective on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Guggenheim set a $224.00 target price on Krystal Biotech and gave the stock a “buy” rating in a research report on Friday, October 17th. Citigroup upgraded shares of Krystal Biotech from a “neutral” rating to a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research report on Monday, September 15th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $228.14.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 13.70% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.